Thomas, D.A., Faderl, S., Cortes, J., O’Brien, S., Giles, F.J., Kornblau, S.M., et al. (2004) Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia with Hyper-CVAD and Imatinibmesylate. Blood, 103, 4396-4407. https://doi.org/10.1182/blood-2003-08-2958

has been cited by the following article:

• TITLE: Diagnostic and Prognostic Significance of Histidine-Rich Glycoprotein in Acute Lymphoblastic Leukemia

  AUTHORS: Manal Basyouni Ahmed, Ebtehal Almogbel, Iman Khirry, Sara Hassan, Tarek Salem, Aliaa Saeed

  KEYWORDS: Acute Lymphoblastic Leukemia, Histidine-Rich Glycoprotein and Serum Markers

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.7 No.1, December 30, 2016

  ABSTRACT: Background: Histidine-rich glycoprotein (HRG), a multifunctional plasma protein, has a regulatory role in homeostasis, angiogenesis, and immunity; which in turn could greatly affect tumor control and metastasis. Objectives: To assess the possible role of HRG in acute lymphoblastic leukemia (ALL) tumorgenesis and follow-up. Design and Methods: HRG was quantitatively measured in serum by ELISA and its expression was assessed by real-time PCR (qPCR) in 35 patients with ALL and compared to same 25 ALL patients after induction therapy and 30 age and sex matched healthy control subjects. Results: HRG-serum protein (at cutoff value 63.55 pg/ml) and HRG-RNA (at cut-off value 0.955) were positive in all ALL patients before therapy, but in only 76% after therapy for HRG-protein and 60% for HRG-RNA and they could not be detected in the control group; P